Severe eosinophilic asthma with IgG subclass deficiency
treated with benralizumab and IVIG: a case report and
literature review

Mehmet Cakmak; Nida Öztop

doi:10.5114/pja.2025.156403

eISSN: 2391-6052
ISSN: 2353-3854

Alergologia Polska - Polish Journal of Allergology

Bieżący numer Archiwum Artykuły zaakceptowane O czasopiśmie Suplementy Zeszyty specjalne Rada naukowa Bazy indeksacyjne Prenumerata Kontakt Zasady publikacji prac Opłaty publikacyjne Standardy etyczne i procedury

Panel Redakcyjny

Zgłaszanie i recenzowanie prac online

Wyszukiwanie

Zasady redakcyjne

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

Otwarty dostęp

4/2025
vol. 12

Poleć ten artykuł:

Wyślij znajomemu

Skopiuj link:

Udostępnij:

streszczenie artykułu:

Opis przypadku

Severe eosinophilic asthma with IgG subclass deficiency treated with benralizumab and IVIG: a case report and literature review

Mehmet E. Cakmak

¹

,

Nida Öztop

¹

Department of Allergy and Clinical Immunology, Başakşehir Çam ve Sakura City Hospital, Istanbul, Türkiye

Alergologia Polska – Polish Journal of Allergology 2025; 12, 4: 327–332

DOI: https://doi.org/10.5114/pja.2025.156403

Data publikacji online: 2025/11/24

Pełna treść artykułu Pobierz cytowanie

Metryki PlumX:

Severe asthma is characterized by poor symptom control and frequent recurrent exacerbations. Primary immunodeficiency with antibody deficiencies are the most common immunodeficiency phenotypes in adult patients and are characterized by frequent recurrent lung infections. Asthma is a common comorbid disease in primary immunodeficiency with antibody deficiencies. The case is presented here of a patient with severe eosinophilic asthma and concomitant immunoglobulin subclass deficiency who was successfully treated with benralizumab and intravenous immunoglobulin (IVIG). After 1 year of benralizumab treatment, improvements were observed in respiratory function tests. During the follow-up, fewer asthma attacks were observed and asthma symptom control improved. The IVIG treatment resulted in decreased antibiotic use for recurrent lung infections in the 1-year period. In cases of severe asthma and accompanying immunodeficiency, asthma treatment and immunodeficiency treatment should be performed together, and biological agent treatments may be required for asthma control.

Severe eosinophilic asthma with IgG subclass deficiency treated with benralizumab and IVIG: a case report and literature review

Mehmet E. Cakmak 1 , Nida Öztop 1

Mehmet E. Cakmak

¹

,

Nida Öztop

¹